Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation and Depletion (2016 - 2024)

Perspective Therapeutics' Depreciation and Depletion history spans 10 years, with the latest figure at -$1.6 million for Q4 2024.

  • For Q4 2024, Depreciation and Depletion fell 250.66% year-over-year to -$1.6 million; the TTM value through Sep 2025 reached -$1.6 million, down 239.89%, while the annual FY2023 figure was $232000.0, 13.11% down from the prior year.
  • Depreciation and Depletion for Q4 2024 was -$1.6 million at Perspective Therapeutics, down from $669000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $669000.0 in Q3 2024 and bottomed at -$1.6 million in Q4 2024.
  • The 5-year median for Depreciation and Depletion is $61500.0 (2021), against an average of $36166.7.
  • The largest annual shift saw Depreciation and Depletion tumbled 310.81% in 2021 before it surged 280.88% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $37000.0 in 2020, then crashed by 310.81% to -$78000.0 in 2021, then skyrocketed by 187.18% to $68000.0 in 2022, then plummeted by 764.71% to -$452000.0 in 2023, then plummeted by 250.66% to -$1.6 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Depreciation and Depletion are -$1.6 million (Q4 2024), $669000.0 (Q3 2024), and $570000.0 (Q2 2024).